Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of allogeneic endothelial progenitor cell injection for acute ischemic stroke
CTR20253094Phase 2Active
- Sponsor
- Chengno Regenerative Medicine
- Start
- Aug 2025
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic endothelial progenitor cells in ischemic stroke, sponsored by Chengno Regenerative Medicine. Started Aug 2025; status: active.
02
Drugs
allogeneic endothelial progenitor cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20253094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253094.